Tech Company Financing Transactions
Cue Biopharma Funding Round
MDB Capital Group and private investors invested in a $26 million funding round for Cue Biopharma. This venture round closed on 1/25/2017.
Transaction Overview
Company Name
Announced On
1/25/2017
Transaction Type
Venture Equity
Amount
$26,000,000
Round
Undisclosed
Investors
MDB Capital Group (Lead Investor)
Proceeds Purpose
Cue will use the proceeds to accelerate development of its novel platform of T cell receptor (TCR) targeted biologics to control immune responses in patients. Cue was founded in 2015 with $10 million of seed funding, followed by a $16.4 million follow-on financing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
21 Erie St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Cue Biopharma (Cue) is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Passeri
Chief Medical Officer
Kenneth Pienta
President
Anish Suri
VP - Finance
Kerri-Ann Millar
VP - General Counsel
Colin Sandercock
Browse more venture capital transactions:
Prev: 1/25/2017: Fuse venture capital transaction
Next: 1/25/2017: Digital Fineprint venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on tech company VC transactions. All VC database entries on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs